Here are four things to know:
1. Goldman, Sachs & Co. will continue to help the company evaluate its strategic alternatives to bolster stockholder value.
2. At this time, Accretive Health has not chosen a specific strategic transaction to drive long term growth and financial performance.
3. The company has not set a time limit for the review, and does not assert that a strategic alternative will be chosen at the end of the process.
4. Accretive Health will not address the end of the review unless it is chooses a transaction with the help of Goldman, Sachs & Co.
Recent articles:
New Jersey Physician sentenced for bribery scheme — 8 facts
Medicare trust fund has money for 15 more years: 5 interesting points
11 things to know about robotic surgery
